Ceritinib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Ceritinib is used to treat metastatic (cancer that has already spread) non-small cell lung cancer in patients who have a certain type of abnormal anaplastic lymphoma kinase (ALK) gene. Your doctor will test for the presence of this gene. Ceritinib is an antineoplastic (cancer) agent.Ceritinib Nitroso Impurity 2 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Ceritinib Nitroso Impurity 2 CAS NO:NA chemically represented as N-(5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)-N-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)nitrous amide. Synchemia is the leading manufacturing and exporter of Ceritinib Nitroso Impurity 2 . We supply Ceritinib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143220 |
| CAS No | NA |
| Mol.F. | C20H31N7OS2 |
| Mol.Wt. | 449.64 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143221 |
| CAS No | NA |
| Mol.F. | C10H16N4O2S |
| Mol.Wt. | 256.32 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143222 |
| CAS No | NA |
| Mol.F. | C11H12ClN5OS2 |
| Mol.Wt. | 329.8 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143223 |
| CAS No | NA |
| Mol.F. | C11H14ClN3O3 |
| Mol.Wt. | 271.7 g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143224 |
| CAS No | NA |
| Mol.F. | C16H17ClN2O |
| Mol.Wt. | 288.8 g/mole |
| INV STATUS | In Stock |
| CAT No | SRC-N0143225 |
| CAS No | NA |
| Mol.F. | C8H14N2O2 |
| Mol.Wt. | 170.21g/mole |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143226 |
| CAS No | NA |
| Mol.F. | C21H20N2O8 |
| Mol.Wt. | 428.39 g/mol |
| INV STATUS | UNDER SYNTHESIS |
| CAT No | SRC-N0143227 |
| CAS No | NA |
| Mol.F. | C12H12N2O2 |
| Mol.Wt. | 254.24g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143228 |
| CAS No | NA |
| Mol.F. | C12H13F2N3O2 |
| Mol.Wt. | 269.25 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143229 |
| CAS No | NA |
| Mol.F. | C12H12FN3O2 |
| Mol.Wt. | 249.25 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143230 |
| CAS No | NA |
| Mol.F. | C40H50N6OS2 |
| Mol.Wt. | 695.0 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143231 |
| CAS No | NA |
| Mol.F. | C18H21N3O3S |
| Mol.Wt. | 359.4 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143232 |
| CAS No | NA |
| Mol.F. | C17H21N3OS |
| Mol.Wt. | 315.44 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143233 |
| CAS No | NA |
| Mol.F. | C16H19N3OS |
| Mol.Wt. | 301.41 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143234 |
| CAS No | NA |
| Mol.F. | C18H21N3O2S |
| Mol.Wt. | 343.45 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143235 |
| CAS No | NA |
| Mol.F. | C18H21N3O2S |
| Mol.Wt. | 343.45 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |